Clinical trials: Docetaxel
Prostate Cancer, Castration Resistant Prostate Cancer
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
This study will evaluate the effect of cabozantinib compared to prednisone on overall survival in men with previously treated metastatic castration-resistant prostate cancer with bone-dominant disease who have experienced disease…
- Conditions
- Prostate Cancer, Castration Resistant Prostate Cancer, Pain, Prostatic Neoplasms
- Trial name
- COMET-1 (NCT01605227)
- Testing
- cabozantinib, prednisone
- Where
- 264 sites in United States, Australia and 12 more
- Volunteers
- 1,028 people
- Sponsor
- Exelixis
Stage I Lung Non-Small Cell Cancer AJCC v7, Stage IA Lung Non-Small Cell Carcinoma AJCC v7
Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer
This phase II trial studies how well nivolumab works when given alone and in combination with ipilimumab or chemotherapy in treating patients with previously untreated stage I-IIIA non-small cell lung cancer.
- Conditions
- Stage I Lung Non-Small Cell Cancer AJCC v7, Stage IA Lung Non-Small Cell Carcinoma AJCC v7, Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7
- Trial name
- NCT03158129
- Testing
- Carboplatin, Cisplatin, Docetaxel
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
Exemestane or Docetaxel-Cytoxan in Low Recurrence Score Cancers
The patients are being asked to take part in this study because they have a hormone receptor-positive breast cancer (contains estrogen and/or progesterone receptors) and their doctor has told them that they have an option to…
- Trial name
- NCT00941330
- Testing
- Exemestane, Docetaxel, Cytoxan
- Where
- 3 sites in United States
- Volunteers
- 31 people
- Sponsor
- Emory University
High-grade Serous Ovarian Carcinoma, Ovarian Carcinoma
Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002)
The primary objective is to evaluate in participants with high-grade serous ovarian cancer (HGSOC), whether the reduction from baseline in circulating tumor deoxyribonucleic acid (ctDNA) at Cycle 3 (ΔctDNA) is larger in…
- Trial name
- NCT05446870
- Testing
- Pembrolizumab, Paclitaxel, Carboplatin
- Where
- 45 sites in United States, Belgium and 9 more
- Volunteers
- 160 people
- Sponsor
- Merck Sharp & Dohme LLC
Breast Cancer, Breast Cancer Female
Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer
This is a one stage phase II study with a single arm design. It will be conducted in HER-2 positive breast cancer patients in Nigeria who are chemotherapy/hormonal treatment naive.
- Conditions
- Breast Cancer, Breast Cancer Female, HER2-positive Breast Cancer, Breast Cancer Stage II
- Trial name
- NCT03879577
- Testing
- Docetaxel, Herceptin, FEC
- Where
- Nigeria
- Volunteers
- 53 people
- Sponsor
- University of Chicago
Endometrial Cancer
Carboplatin, Docetaxel, and Radiation Therapy in Treating Patients With Stage III/IV, or Recurrent Endometrial Cancer
RATIONALE: Drugs used in chemotherapy, such as carboplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00258362
- Testing
- carboplatin, docetaxel, radiation therapy
- Where
- 2 sites in United States
- Volunteers
- 41 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Metastatic Triple Negative Breast Cancer
L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients
This is a Phase Ib/II study assessing the maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), recommended Phase 2 dose (RP2D), and efficacy of L-NMMA when combined with docetaxel in refractory locally advanced or…
- Trial name
- NCT02834403
- Testing
- L-NMMA, Docetaxel, Amlodipine
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- The Methodist Hospital Research Institute
Breast Cancer
NOV-002, Doxorubicin, Cyclophosphamide, and Docetaxel in Women With Newly Diagnosed Stage II or IIIC Breast Cancer
RATIONALE: Oxidized glutathione (NOV-002) may stimulate the immune system in different ways and stop tumor cells from growing. Drugs used in chemotherapy, such as doxorubicin, cyclophosphamide, and docetaxel, work in different…
- Trial name
- NCT00499122
- Testing
- Cyclophosphamide, Docetaxel, Doxorubicin
- Where
- 2 sites in United States
- Volunteers
- 41 people
- Sponsor
- University of Miami
Non-Small Cell Lung Cancer
Phase III Study (Tarceva®) vs Chemotherapy to Treat Advanced Non-Small Cell Lung Cancer in Patients With Mutations in the TK Domain of EGFR
A Phase III, multicenter, open-label, randomized trial of Erlotinib (Tarceva®) versus chemotherapy in patients with advanced NSCLC with mutations in the Tyrosine Kinase (TK) domain of the EGFR.
- Trial name
- EURTAC (NCT00446225)
- Testing
- Erlotinib, Carboplatin, Gemcitabin
- Where
- 76 sites in France, Italy and 1 more
- Volunteers
- 174 people
- Sponsor
- Spanish Lung Cancer Group
Head and Neck Cancer
Adjuvant Cetuximab and Chemoradiotherapy Using Either Cisplatin or Docetaxel in Treating Patients With Resected Stage III or Stage IV Squamous Cell Carcinoma or Lymphoepithelioma of the Head and Neck
RATIONALE: Monoclonal antibodies such as cetuximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00084318
- Testing
- cetuximab, cisplatin, docetaxel
- Where
- 160 sites in United States
- Volunteers
- 238 people
- Sponsor
- Radiation Therapy Oncology Group
Prostatic Neoplasms
Abiraterone Acetate in Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
This is a phase 3 study to compare the clinical benefit of abiraterone acetate plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer (CRPC) who have failed one or two…
- Trial name
- NCT00638690
- Testing
- Abiraterone acetate, Prednisone/prednisolone
- Where
- 127 sites in United States, Australia and 10 more
- Volunteers
- 1,195 people
- Sponsor
- Cougar Biotechnology, Inc.
Breast Cancer
Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients
This is an open-label study that includes two substudies of random distribution. First,a sample of the primary tumor will be obtained and will be analyzed by an immunohistochemical technique to determine several markers.Depending…
- Trial name
- NCT00432172
- Testing
- Epirubicin, Cyclophosphamide, Docetaxel
- Where
- 12 sites in Spain
- Volunteers
- 189 people
- Sponsor
- Spanish Breast Cancer Research Group
Transitional Cell Carcinoma, Bladder Cancer
Randomized Study of Docetaxel +/- Vandetanib in Metastatic TCC
In this research study the investigators are looking to see if the combination of docetaxel plus Vandetanib is effective in the treatment of metastatic transitional cell carcinoma (TCC).
- Trial name
- NCT00880334
- Testing
- Docetaxel, vandetanib
- Where
- 3 sites in United States
- Volunteers
- 149 people
- Sponsor
- Dana-Farber Cancer Institute
Prostatic Neoplasms
Docetaxel, Thalidomide, Prednisone, and Bevacizumab to Treat Metastatic Prostate Cancer
This is a Phase II study of docetaxel, bevacizumab, prednisone and thalidomide in patients with androgen independent metastatic prostate cancer who are previously untreated with chemotherapy.
- Trial name
- NCT00089609
- Testing
- Docetaxel, Thalidomide, Prednisone
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Non Small Cell Lung
A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
The primary objective of the study was to demonstrate overall survival improvement for aflibercept + docetaxel compared to docetaxel + placebo as second line treatment for participants with locally advanced or metastatic…
- Trial name
- VITAL (NCT00532155)
- Testing
- Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®), Docetaxel (Taxotere®), Dexamethasone (pre- and post-medication for docetaxel)
- Where
- 32 sites in United States, Argentina and 30 more
- Volunteers
- 913 people
- Sponsor
- Sanofi
Breast Cancer, Breast Neoplasms
Vaccination of High Risk Breast Cancer Patients - A Combined Phase I/II Feasibility-and-Efficacy Study
The purpose of this study is to evaluate a new investigational cancer vaccine, P10s-PADRE in combination with standard neoadjuvant chemotherapy and surgery in patients with clinical stage I, II or III estrogen-receptor…
- Trial name
- NCT02229084
- Testing
- P10s-PADRE/ MONTANIDE™ ISA 51 VG, Doxorubicin, Cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 58 people
- Sponsor
- University of Arkansas
Metastatic Hormone-sensitive Prostate Cancer
Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Androgens can cause the growth of prostate cancer cells. Androgen ablation therapy may stop the adrenal glands from making androgens.
- Trial name
- CHAARTED (NCT00309985)
- Testing
- androgen-deprivation therapy, docetaxel
- Where
- 343 sites in United States
- Volunteers
- 790 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Lung Cancer, Non Small Cell Lung Cancer
0822GCC: Phase 2 Study of Efficacy and Safety of Apricoxib/Placebo With Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer
The primary objective is to determine the anti-tumor activity of the combination of apricoxib + either docetaxel (AP/DC) or pemetrexed (AP/PE) compared with placebo + either docetaxel (P/DC) or pemetrexed (P/PE) as measured by…
- Trial name
- NCT00771953
- Testing
- apricoxib, Docetaxel or Pemetrexed
- Where
- 12 sites in United States
- Volunteers
- 109 people
- Sponsor
- University of Maryland, Baltimore
Androgen-independent Prostate Cancer
Mitoxantrone ± Cetuximab 2nd Line Androgen Independent Prostate Cancer (AIPC)
To determine the time to progression produced by the combination of Novantrone (mitoxantrone) and Erbitux (cetuximab) versus Novantrone alone in metastatic AIPC patients previously treated with docetaxel-based chemotherapy.
- Trial name
- NCT00661492
- Testing
- cetuximab, Mitoxantrone
- Where
- 55 sites in United States
- Volunteers
- 115 people
- Sponsor
- US Oncology Research
First-line Treatment for Patients With Non-resectable Gastric Cancer or Cancer of the Esophagus or
Chemotherapy for Patients With Cancer of the Stomach
The purpose of this study is to determine maximal tolerable dose (MTD) of the combination of docetaxel, oxaliplatin and S1 (DOS) to patients with gastric cancer.
- Trial name
- DOS (NCT01928524)
- Testing
- DOS2w Dose level 1A, DOS2w Dose level 2A, DOS2w Dose level 3A
- Where
- Denmark
- Volunteers
- 34 people
- Sponsor
- Per Pfeiffer